French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of advanced/relapsing endometrial cancer

Histomolecular diagnosis of endometrial cancer systematically includes the evaluation of hormonal receptors, P53 and MMR statutes (determination of PD-L1 and HRD statutes is not required). Therapeutic progress in advanced endometrial cancer is mainly related to the first-line utilization of immunotherapy associated with chemotherapy, a strategy assessed in five randomized controlled trials, although at the moment, only dostarlimab is available in France. Immunotherapy administration requires specific pretherapeutic workup and monitoring. Hormone therapy remains an option in non-aggressive, low grade endometrioid cancer, expressing hormone receptors. Treatment choice is based on clinical situation (upfront metastatic disease or relapse after adjuvant therapy, and duration of platinum-free interval in case of adjuvant therapy), disease aggressivity, molecular status (in particular, MMR status) and patients' comorbidities. PARP inhibitors are not recommended as maintenance therapy. In second line, the combination of pembrolizumab and lenvatinib is the standard treatment if chemoimmunotherapy has not been used previously. If it has been, therapeutic strategy depends on the duration of platinum-free interval. Inclusion in a clinical trial should always be considered when the patient's performance status makes it possible. The choice of the trial is guided by HER2 status in immunohistochemistry and results of new generation sequencing when available. The current trend towards the development of personalized medicine highlights the importance of pathological and molecular characterization of the tumor.

Published by Bulletin du cancer, 2026. The guideline itself is at the source linked here.

doi.org/10.1016/j.bulcan.2026.01.001